Answers are grounded in this paper and cite their sources.
Pimitespib as a new treatment option in the fourth-line setting did not negatively impact HRQoL overall, with the exception of diarrhea and appetite loss, in patients with metastatic GIST.
No takes yet. Share an insight, caveat, or question.
Komatsu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: